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Use of Most Bothersome Symptom as a Coprimary Endpoint
in Migraine Clinical Trials: A Post-Hoc Analysis of the
Pivotal ZOTRIP Randomized, Controlled Trial
David W. Dodick, MD; Stewart J. Tepper, MD; Deborah I. Friedman, MD; Amy A. Gelfand, MD;
Donald J. Kellerman, PharmD; Peter C. Schmidt, MD, MSc
Objective.—To better understand the utility of using pain freedom and most bothersome headache-associated symp-
tom (MBS) freedom as co-primary endpoints in clinical trials of acute migraine interventions.
Background.—Adhesive dermally applied microarray (ADAM) is an investigational system for intracutaneous drug adminis-
tration. The recently completed pivotal Phase 2b/3 study (ZOTRIP), evaluating ADAM zolmitriptan for the treatment of acute
moderate to severe migraine, was one of the first large studies to incorporate MBS freedom and pain freedom as co-primary end-
points per recently issued guidance by the US Food and Drug Administration. In this trial, the proportion of patients treated with
ADAM zolmitriptan 3.8 mg, who were pain-free and MBS-free at 2 hours post-dose, was significantly higher than for placebo.
Methods.—We undertook a post-hoc analysis of data from the ZOTRIP trial to examine how the outcomes from this
trial compare to what might have been achieved using the conventional co-primary endpoints of pain relief, nausea, photo-
phobia, and phonophobia.
Results.—Of the 159 patients treated with ADAM zolmitriptan 3.8 mg or placebo, prospectively designated MBS
were photophobia (n5 79), phonophobia (n5 43), and nausea (n5 37). Two-hour pain free rates in those with photophobia
as the MBS were 36% for ADAM zolmitriptan 3.8 mg and 14% for placebo (P5 .02). Corresponding rates for those with
phonophobia as the MBS were 14% and 41% (P5 .05). For those whose MBS was nausea, corresponding values were
56% and 16%, respectively (P5 .01). Two-hour freedom from the MBS for active drug vs placebo were 67% vs 35%
(P< .01) for photophobia, 55% vs 43% (P5 .45) for phonophobia, and 89% vs 58% for nausea (P5 .04). MBS freedom
but not pain freedom was achieved in 28%. Only 1 patient (1%) achieved pain freedom, but not MBS freedom. The pro-
portion with both pain and MBS freedom was highest (56%) among those whose MBS was nausea.
Conclusion.—In this study, the use of MBS was feasible and seemed to compare favorably to the previously required
4 co-primary endpoints.
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Primary efficacy endpoints in clinical trials of
acute migraine medications have evolved over time
and have included headache response/relief
(improvement from moderate to severe pain at
baseline to mild or no pain 2-hour post-dose); pain
freedom at 2 hours post-dose; and the co-primary
endpoints of pain relief, nausea, photophobia, and
phonophobia.1,2 In February 2018, the US Food
and Drug Administration (FDA) issued a final
guidance document for developing drugs for the
acute treatment of migraine.1 The guidance sug-
gested an alternative, preferred approach: having
patients specify their most bothersome migraine-
associated symptom (MBS) other than pain, either
at a baseline visit or at the time of the attack, and
using MBS freedom and pain freedom as co-
primary endpoints. Per the guidance, the use of
this endpoint “aims to better align the study
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outcome with the symptom(s) of primary impor-
tance to patients.” This approach may also sub-
stantially reduce the burden of conducting trials
with 4 co-primary endpoints, while still addressing
the need to alleviate migraine-associated symp-
toms in addition to pain, and may better harmo-
nize migraine randomized controlled trial design
with “real world” treatment experience, as has
been suggested in the case of cluster headache
trials.3
Adhesive dermally applied microarray (ADAM)
is an investigational system for intracutaneous drug
administration. In a Phase 1 study evaluating the
pharmacokinetics of zolmitriptan delivered with
ADAM, absorption was considerably faster than for
oral zolmitriptan, with higher exposure in the first 2
hours.4 The recently completed pivotal Phase 2b/3
study (ZOTRIP, NCT02745392), evaluating ADAM
zolmitriptan for the treatment of acute moderate to
severe migraine, was one of the first large studies to
incorporate MBS freedom and pain freedom as co-
primary endpoints. In this trial, the proportion of
patients treated with ADAM zolmitriptan 3.8 mg,
who were pain-free and MBS-free at 2 hours post-
dose (co-primary endpoints), was significantly higher
than for placebo.5
As this is the only published pivotal acute
migraine trial using pain freedom and MBS freedom
as co-primary endpoints,5 we undertook a post-hoc
analysis of the ZOTRIP trial to better understand the
utility of this approach and the relationships among
achieving each of the endpoints. Specifically, our aims
were to provide summary statistics for each MBS
group, to compare response rates and time course of
response among each of these groups, and to examine
the correlation between MBS freedom and pain free-
dom. We were further interested in how the results
might theoretically differ if the trial had been
designed using the traditional 4 co-primary endpoints.
METHODS
This was a multicenter, randomized, double-
blind, placebo-controlled, parallel group, Phase
2b/3 study conducted at 36 sites in the US.
Detailed methods and primary study results were
previously reported.5 Eligible patients experienced
2-8 migraine headaches (with or without aura) dur-
ing a 28-day run-in period. On the first day of the
run-in period, patients declared the MBS other than
pain occurring most of the time with their migraine
headaches, choosing prospectively among nausea
(with or without vomiting), photophobia, or phono-
phobia. Patients were randomly assigned in a 1:1:1:1
ratio, stratified by MBS, to receive ADAM zolmi-
triptan 1 mg, 1.9 mg, 3.8 mg, or placebo to treat 1
migraine at moderate or severe levels of pain.
Patients were required to have their prospectively
chosen MBS as one of their symptoms for the head-
ache to qualify for treatment. Symptoms were
recorded using an electronic diary (e-Diary).
The co-primary endpoints of the study were the
proportion of patients reporting pain freedom at 2
hours post-dose and the proportion reporting MBS
freedom at 2 hours post-dose. Prespecified second-
ary endpoints included (but were not limited to)
freedom at 2 hours post-dose from photophobia,
phonophobia, or nausea (irrespective of MBS).
All authors had full access to all study data.
Data were analyzed via Cochran–Mantel–
Haenszel (CMH) test stratified by MBS. A fixed
sequential testing methodology was applied to con-
trol the overall type 1 error. A test was considered
statistically significant only if the corresponding
CMH test had a P value <.05 and all previous tests
had a P value <.05. Last observation carried for-
ward was used to impute missing data.
For the post-hoc analyses presented here
(Table 1), CMH testing was also employed. Data
are only reported for the 3.8 mg dose and placebo,
as this was the only dose that clearly showed a sig-
nificant treatment effect for the co-primary end-
points of pain freedom and MBS freedom at 2
hours post-dose.
RESULTS
A total of 365 patients were randomized; 321
were treated and had at least 1 post-treatment
symptom assessment (mITT population). Patient
demographics and baseline characteristics as well as
primary study results were reported previously.5 Of
the 321 treated, 77 received placebo and 82 were
treated with ADAM zolmitriptan 3.8 mg.
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For the primary outcome measures, 11 (14%)
patients receiving placebo and 34 (42%) of patients
receiving ADAM zolmitriptan 3.8 mg were pain-
free at 2 hours post-dose (P< .01), and 33 (43%)
patients receiving placebo and 56 (68%) patients
receiving ADAM zolmitriptan 3.8 mg were free
from MBS (P< .01).5
The most frequently prespecified MBS was
photophobia, chosen by 79 patients (50%), 37 of
whom received placebo and 42 ADAM zolmitrip-
tan 3.8 mg. Phonophobia was the next most com-
monly chosen, by a total of 43 patients (27%), 21
of whom were assigned to placebo and 22 to
ADAM zolmitriptan 3.8 mg. Nausea was selected
as the MBS for 37 (23%) patients, 19 in the pla-
cebo group and 18 in the ADAM zolmitriptan
3.8 mg group.
Among patients with photophobia or nausea as
their MBS, significantly more patients in the
ADAM zolmitriptan 3.8 mg group were pain-free
and/or MBS-free at 2 hours post-dose compared
with those who received placebo (Table 1). In
patients whose MBS was phonophobia, the differ-
ence between ADAM zolmitriptan 3.8 mg and pla-
cebo was not significant for either pain freedom or
MBS freedom at 2 hours post-dose.
To evaluate how frequently 2-hour pain free-
dom and 2-hour MBS freedom coincided, we deter-
mined the percentages of patients who achieved
both 2-hour pain freedom and 2-hour MBS-
freedom, freedom from either pain or MBS, and
those who did not achieve either pain or MBS free-
dom (Figure 1). Overall, 33 (40%) patients in the
ADAM zolmitriptan 3.8 mg group and 11 (14%) in
the placebo group were both pain-free and MBS-
free at 2 hours post dose. Freedom from MBS, but
not from pain, occurred in 23 (28%) patients in the
ADAM zolmitriptan 3.8 mg group and 22 (29%) in
the placebo group. Only 1 patient (1%) achieved
freedom from pain, but not from their MBS; this
patient reported photophobia as their MBS. In the
ADAM zolmitriptan 3.8 mg group, the proportion
who reported both 2-hour pain freedom and MBS-
freedom was highest (n5 10, 56%) among those
whose MBS was nausea. This proportion was small-
est (n5 14, 33%) among those whose MBS was
photophobia.
Figure 2 shows the time course of pain freedom
and MBS freedom. Overall, the percentage of
patients who achieved pain freedom in the ADAM
zolmitriptan 3.8 mg group increased over the course
of 4 hours post-dose. Freedom from MBS appeared
to occur more rapidly than pain freedom with only
a slight increase in the number who achieved MBS
freedom between 2 and 4 hours.
All patients in this trial were required to have a
qualifying migraine that included the presence of their
prespecified MBS, even if that symptom was not the
Table 1.—Percentage of Patients Who Had 2-Hour Pain Freedom or 2-Hour MBS Freedom by Prespecified MBS
(mITT Population)
Photophobia Phonophobia Nausea
Placebo,
n5 37
ADAM
Zolmitriptan
3.8 mg, n5 42
Placebo,
n5 21
ADAM
Zolmitriptan
3.8 mg, n5 22
Placebo,
n5 19
ADAM
Zolmitriptan5
3.8 mg, n5 18
2-hour pain freedom, n (%) 5 (14) 15 (36) 3 (14) 9 (41) 3 (16) 10 (56)
Treatment difference† 22% 27% 40%
P value‡ .02 .05 .01
2-hour MBS freedom, n (%) 13 (35) 28 (67) 9 (43) 12 (55) 11 (58) 16 (89)
Treatment difference† 32% 12% 31%
P value‡ <.01 .45 .04
†ADAM zolmitriptan 3.8 mg minus placebo.
‡ADAM zolmitriptan 3.8 mg vs placebo.
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most bothersome at the time of that particular head-
ache. As shown in Table 2, the percentage of patients
who reported the presence of one or more of photo-
phobia, phonophobia, or nausea at the time of treat-
ment was considerably higher than the percentage who
chose each of these symptoms as prespecified MBS.
Table 2 also presents the results corresponding
to the previously often-used 4 co-primary endpoints:
pain relief, and absence of nausea, photophobia, and
phonophobia at 2 hours post-dose. The latter 3 end-
points were secondary endpoints in this pivotal trial
and although nominal statistical superiority was
achieved for absence of photophobia and phonopho-
bia, due to the fixed sequential testing methodology
employed, formal statistical significance was not
established for any of these endpoints.
DISCUSSION
In the last 25 years, new therapies for the acute
treatment of migraine have been evaluated in stud-
ies with 4 primary endpoints at 2 hours post-treat-
ment: pain relief, photophobia freedom,
phonophobia freedom, and nausea freedom. Pain
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freedom is now recommended in place of pain
relief as a primary efficacy endpoint, as it is consid-
ered more clinically meaningful. It is also the rec-
ommended primary endpoint for acute migraine
treatment trials by the International Headache
Society.5 The major associated symptoms of
migraine—photophobia, phonophobia, and nau-
sea—are important for assessing a therapy’s effect
on the migraine, but all symptoms are not always
present. For example, nausea rates at the time of
treatment range anywhere from 40% to 70%.6
Therefore, requiring the elimination of a symptom
that was never present and requiring a therapy to
have a higher response rate than placebo in nausea
freedom at 2 hours may require a large sample size
per treatment group. The designation of MBS pre-
randomization, and the requirement that the symp-
tom be present at the time of treatment, solves the
problem of any given symptom being absent at the
time of treatment and allows for a proper compari-
son of the differential effect of active vs placebo.
The ZOTRIP trial is the only published pivotal
trial to use prespecified usual MBS freedom as a
co-primary endpoint along with pain freedom at
2 hours.5 In this multicenter, randomized, double-
blind, placebo-controlled, parallel group Phase 2b/3
study, patients treated with ADAM zolmitriptan
3.8 mg were significantly more likely to be pain-
free and/or MBS-free at 2 hours post-treatment
than those receiving placebo.5 Approximately 80
patients per treatment group were sufficient to
show a clear difference between an effective ther-
apy and placebo. Using the previous 4 co-primary
endpoints, ADAM-Zolmitriptan 3.8 mg would have
also been found to be effective for pain relief, nau-
sea, and photophobia (Table 2). The study was not
powered for the 4 endpoints, however, and the P
value for phonophobia was .06 for ADAM-
Zolmitriptan 3.8 mg, suggesting a larger sample size
is needed to reach significance on this endpoint.
Using a 2-sided Mantel-Haenszel test in 3 strata
and assuming a significance level of 0.05 and 80%
power, 170 subjects per group are needed. Con-
sidering this, our experience with MBS in this trial
suggests that its use may be an improvement over
requiring statistically significant improvement for
each of the endpoints of photophobia freedom,
phonophobia freedom, and nausea freedom to dem-
onstrate efficacy. The MBS endpoint may allow for
smaller, faster, and less expensive trials to be con-
ducted without any loss in sensitivity.
In this trial, patients’ treatment assignment was
stratified based on prespecified (on the first day of
the run-in period) MBS to avoid imbalance across
treatment groups. We chose this approach as it
would have been logistically cumbersome and bur-
densome to subjects to withhold drug assignment
until the time of a migraine in an outpatient study,
especially in this trial in which there were 4 possi-
ble treatments. Given that an individual’s migraine-
associated symptoms often vary from attack to
attack, requiring patients to pre-select MBS has the
inherent risk that the selected MBS may not be
present or is not their most bothersome symptom
when they treat the migraine headache. This study
controlled for this by not allowing patients to treat
unless their prespecified MBS was present. Future
studies might also add a question to the e-Diary to
assess how many times there is discordance
between the preselected most bothersome symptom
and which symptom is the most bothersome symp-
tom at the time of treatment.
Table 2.—Characteristics of Qualifying Migraine at the Time
of Treatment and Symptom Relief/Freedom at 2 Hours
Post-Dose (mITT Population)
Placebo,
n5 77,
n (%)
ADAM
Zolmitriptan
3.8 mg, n5 82,
n (%) P value†
Characteristics of qualifying migraine
Photophobia present 75 (97) 78 (95) —
Phonophobia present 72 (94) 71 (87) —
Nausea present 51 (66) 59 (72) —
Outcomes 2 hours post-dose
Pain relief‡ 40 (59) 55 (80) <.01
Photophobia-free 32 (42) 57 (70) <.01
Phonophobia-free 43 (56) 57 (70) .06
Nausea-free 49 (64) 67 (82) .01
†Nominal P value ADAM zolmitriptan 3.8 mg vs placebo
due fixed sequential testing.
‡Defined as improvement to a rating of none or mild with-
out the use of rescue medications.
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An important finding in this trial was that only
1 patient (<1%) achieved pain freedom without
achieving MBS freedom. In addition, the placebo
response rate for 2-hour MBS freedom (42%) was
substantially higher than that for 2-hour pain free-
dom (14%) in this trial,5 as has been observed in
other trials,6,7 which may increase the number of
trial participants necessary to show freedom for
both endpoints. Further work is required to eluci-
date if this concordance rate is maintained across
trials. If so, it may argue for the feasibility of a sin-
gle pain freedom endpoint in the future as a means
to decrease trial cost and duration.
The limitation of this analysis is its post-hoc
nature. Results should therefore be considered pre-
liminary and the usefulness of including MBS as a
co-primary endpoint will require confirmation in
additional and larger studies.
CONCLUSIONS
Experience in the ZOTRIP trial indicates that
MBS as a co-primary endpoint is a feasible and desir-
able alternative to using 4 co-primary endpoints in
acute migraine treatment trials. Furthermore, the trial
demonstrated a very high concordance rate between
MBS freedom and pain freedom.
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